Erfo, exercised option to sell 49% of FRCM1 to Farmacosmo

AATech reduces loss to 023 million euros in 2023

(Finance) – Erfo Pharmaceutical Laboratorya company operating in the nutraceutical sector and listed on Euronext Growth Milan, has notified a Pharmacosmosa company listed on Euronext Growth Milan and active in the Health, Pharma & Beauty sector, the desire to exercise the potestative right of sell (Put Option) to the latter his own shareholding held in FRCM1.

This option was exercised by virtue of the agreement signed with Farmacosmo in April 2024. Within 30 days from today, Farmacosmo will therefore purchase the entire shareholding held by Erfo in FRCM1, equal to 49% of the capital, at consideration set at 151,900 euros.

There choice to exercise the option was determined by the opportunity to focus, in this specific historical moment, on strategies that lead to greater industrial synergies, we read in a note.

(Photo: Scott Graham on Unsplash)

tlb-finance